Open Nav

Please submit your session questions in advance at

Arcturus Therapeutics

  • Joseph Payne, Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Ltd. (NASDAQ: ARCT) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR® lipid-mediated delivery. Arcturus’ diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (140 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus’ commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG and the Cystic Fibrosis Foundation. For more information, visit, the content of which is not incorporated herein by reference.

  • Date:Monday, February 11
  • Time:9:15 AM - 9:30 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23278
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Company Overview, Pipeline, Delivery Platform
  • Company Website:
  • Company HQ City:San Diego
  • Company HQ State:California
  • Company HQ Country:United States
  • Market Cap:70 Million
  • Ticker:ARCT
  • Exchange:Nasdaq
  • CEO/Top Company Official:Joseph Payne
  • Year Founded:2013
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development:LUNAR-OTC
  • Development Phase of Primary Product:Pre-Clinical
Joseph Payne
Arcturus Therapeutics